Logo image of NUTX

NUTEX HEALTH INC (NUTX) Stock Fundamental Analysis

NASDAQ:NUTX - Nasdaq - US67079U3068 - Common Stock - Currency: USD

147.73  +21.8 (+17.31%)

Fundamental Rating

5

Overall NUTX gets a fundamental rating of 5 out of 10. We evaluated NUTX against 102 industry peers in the Health Care Providers & Services industry. Both the profitability and the financial health of NUTX get a neutral evaluation. Nothing too spectacular is happening here. NUTX is not overvalued while it is showing excellent growth. This is an interesting combination. With these ratings, NUTX could be worth investigating further for growth investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

NUTX had positive earnings in the past year.
NUTX had a positive operating cash flow in the past year.
NUTX had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: NUTX reported negative operating cash flow in multiple years.
NUTX Yearly Net Income VS EBIT VS OCF VS FCFNUTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M -400M

1.2 Ratios

With an excellent Return On Assets value of 7.96%, NUTX belongs to the best of the industry, outperforming 92.16% of the companies in the same industry.
With an excellent Return On Equity value of 35.65%, NUTX belongs to the best of the industry, outperforming 96.08% of the companies in the same industry.
NUTX has a Return On Invested Capital of 23.08%. This is amongst the best in the industry. NUTX outperforms 95.10% of its industry peers.
Industry RankSector Rank
ROA 7.96%
ROE 35.65%
ROIC 23.08%
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NUTX Yearly ROA, ROE, ROICNUTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

NUTX has a Profit Margin of 10.87%. This is amongst the best in the industry. NUTX outperforms 96.08% of its industry peers.
Looking at the Operating Margin, with a value of 28.69%, NUTX belongs to the top of the industry, outperforming 98.04% of the companies in the same industry.
NUTX's Gross Margin of 40.89% is fine compared to the rest of the industry. NUTX outperforms 69.61% of its industry peers.
In the last couple of years the Gross Margin of NUTX has remained more or less at the same level.
Industry RankSector Rank
OM 28.69%
PM (TTM) 10.87%
GM 40.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
NUTX Yearly Profit, Operating, Gross MarginsNUTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K -4K -6K -8K -10K

More info and screens

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), NUTX is creating value.
The number of shares outstanding for NUTX has been reduced compared to 1 year ago.
Compared to 5 years ago, NUTX has more shares outstanding
The debt/assets ratio for NUTX has been reduced compared to a year ago.
NUTX Yearly Shares OutstandingNUTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
NUTX Yearly Total Debt VS Total AssetsNUTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

NUTX has an Altman-Z score of 1.76. This is a bad value and indicates that NUTX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.76, NUTX is in line with its industry, outperforming 45.10% of the companies in the same industry.
The Debt to FCF ratio of NUTX is 14.75, which is on the high side as it means it would take NUTX, 14.75 years of fcf income to pay off all of its debts.
With a Debt to FCF ratio value of 14.75, NUTX perfoms like the industry average, outperforming 45.10% of the companies in the same industry.
A Debt/Equity ratio of 1.95 is on the high side and indicates that NUTX has dependencies on debt financing.
With a Debt to Equity ratio value of 1.95, NUTX is not doing good in the industry: 76.47% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.95
Debt/FCF 14.75
Altman-Z 1.76
ROIC/WACC3.17
WACC7.27%
NUTX Yearly LT Debt VS Equity VS FCFNUTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

NUTX has a Current Ratio of 2.08. This indicates that NUTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.08, NUTX is in the better half of the industry, outperforming 75.49% of the companies in the same industry.
A Quick Ratio of 2.06 indicates that NUTX has no problem at all paying its short term obligations.
NUTX has a Quick ratio of 2.06. This is in the better half of the industry: NUTX outperforms 76.47% of its industry peers.
Industry RankSector Rank
Current Ratio 2.08
Quick Ratio 2.06
NUTX Yearly Current Assets VS Current LiabilitesNUTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 294.00% over the past year.
Looking at the last year, NUTX shows a very strong growth in Revenue. The Revenue has grown by 93.81%.
Measured over the past years, NUTX shows a very strong growth in Revenue. The Revenue has been growing by 222.96% on average per year.
EPS 1Y (TTM)294%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1421.92%
Revenue 1Y (TTM)93.81%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%269.77%

3.2 Future

Based on estimates for the next years, NUTX will show a very negative growth in Earnings Per Share. The EPS will decrease by -27.81% on average per year.
Based on estimates for the next years, NUTX will show a very strong growth in Revenue. The Revenue will grow by 28.17% on average per year.
EPS Next Y-52.49%
EPS Next 2Y-27.81%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year53.08%
Revenue Next 2Y28.17%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NUTX Yearly Revenue VS EstimatesNUTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M 400M 500M
NUTX Yearly EPS VS EstimatesNUTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 0 -20 -40 -60 -80 -100

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 16.92, NUTX is valued correctly.
78.43% of the companies in the same industry are more expensive than NUTX, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of NUTX to the average of the S&P500 Index (24.95), we can say NUTX is valued slightly cheaper.
The Price/Forward Earnings ratio is 35.61, which means the current valuation is very expensive for NUTX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NUTX is on the same level as its industry peers.
NUTX is valuated expensively when we compare the Price/Forward Earnings ratio to 20.99, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 16.92
Fwd PE 35.61
NUTX Price Earnings VS Forward Price EarningsNUTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

NUTX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. NUTX is cheaper than 89.22% of the companies in the same industry.
NUTX's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 39.18
EV/EBITDA 6.11
NUTX Per share dataNUTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80

4.3 Compensation for Growth

The decent profitability rating of NUTX may justify a higher PE ratio.
NUTX's earnings are expected to decrease with -27.81% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.81%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NUTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUTEX HEALTH INC

NASDAQ:NUTX (5/14/2025, 1:34:40 PM)

147.73

+21.8 (+17.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-06 2025-05-06
Earnings (Next)08-06 2025-08-06
Inst Owners16.4%
Inst Owner Change-82.43%
Ins Owners2.22%
Ins Owner Change0%
Market Cap816.95M
Analysts82.22
Price Target104.04 (-29.57%)
Short Float %3.49%
Short Ratio1.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.25
Dividend Growth(5Y)N/A
DP12.34%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4168.53%
Min EPS beat(2)-602.61%
Max EPS beat(2)8939.67%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)108.41%
Min Revenue beat(2)5.5%
Max Revenue beat(2)211.33%
Revenue beat(4)4
Avg Revenue beat(4)57.06%
Min Revenue beat(4)2.05%
Max Revenue beat(4)211.33%
Revenue beat(8)4
Avg Revenue beat(8)26.6%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)60.21%
PT rev (3m)84.34%
EPS NQ rev (1m)55.78%
EPS NQ rev (3m)1054.17%
EPS NY rev (1m)227.08%
EPS NY rev (3m)227.08%
Revenue NQ rev (1m)11.92%
Revenue NQ rev (3m)43.83%
Revenue NY rev (1m)13.16%
Revenue NY rev (3m)33.81%
Valuation
Industry RankSector Rank
PE 16.92
Fwd PE 35.61
P/S 1.7
P/FCF 39.18
P/OCF 35.28
P/B 5.58
P/tB 6.99
EV/EBITDA 6.11
EPS(TTM)8.73
EY5.91%
EPS(NY)4.15
Fwd EY2.81%
FCF(TTM)3.77
FCFY2.55%
OCF(TTM)4.19
OCFY2.83%
SpS86.79
BVpS26.46
TBVpS21.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.96%
ROE 35.65%
ROCE 26.77%
ROIC 23.08%
ROICexc 25.2%
ROICexgc 26.86%
OM 28.69%
PM (TTM) 10.87%
GM 40.89%
FCFM 4.34%
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
F-Score7
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 1.95
Debt/FCF 14.75
Debt/EBITDA 1.82
Cap/Depr 12.14%
Cap/Sales 0.48%
Interest Coverage 39.67
Cash Conversion 14.78%
Profit Quality 39.96%
Current Ratio 2.08
Quick Ratio 2.06
Altman-Z 1.76
F-Score7
WACC7.27%
ROIC/WACC3.17
Cap/Depr(3y)59.19%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)294%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1421.92%
EPS Next Y-52.49%
EPS Next 2Y-27.81%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)93.81%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%269.77%
Revenue Next Year53.08%
Revenue Next 2Y28.17%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10758.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year83.45%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y353%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1743.46%
OCF growth 3YN/A
OCF growth 5YN/A